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ABSTRACT
In our prior publications we characterized a conserved acetylation motif (K(R)
xxKK) of evolutionarily related nuclear receptors. Recent reports showed that
peroxisome proliferator activated receptor gamma (PPARγ) deacetylation by SIRT1
is involved in delaying cellular senescence and maintaining the brown remodeling
of white adipose tissue. However, it still remains unknown whether lysyl residues
154 and 155 (K154/155) of the conserved acetylation motif (RIHKK) in Pparγ1 are
acetylated. Herein, we demonstrate that Pparγ1 is acetylated and regulated by both
endogenous TSA-sensitive and NAD-dependent deacetylases. Acetylation of lysine
154 was identified by mass spectrometry (MS) while deacetylation of lysine 155
by SIRT1 was confirmed by in vitro deacetylation assay. An in vivo labeling assay
revealed K154/K155 as bona fide acetylation sites. The conserved acetylation sites
of Pparγ1 and the catalytic domain of SIRT1 are both required for the interaction
between Pparγ1 and SIRT1. Sirt1 and Pparγ1 converge to govern lipid metabolism
in vivo. Acetylation-defective mutants of Pparγ1 were associated with reduced lipid
synthesis in ErbB2 overexpressing breast cancer cells. Together, these results suggest
that the conserved lysyl residues K154/K155 of Pparγ1 are acetylated and play an
important role in lipid synthesis in ErbB2-positive breast cancer cells.

INTRODUCTION

in many tissues at low levels, while PPARγ2 is expressed
at high levels and is restricted to adipose tissue. Mouse
PPARγ1 and human PPARγ1 shared 98% homology in
protein sequence. PPAR regulates diverse biological
functions including adipocyte differentiation [1],
lipogenesis [2], inflammation [3], insulin sensitivity [4],
cellular proliferation [5], and autophagy [6]. Both natural
ligands including prostaglandins (15d-PGJ2) and synthetic
ligands including the anti-diabetic thiazolidinediones
(TZD) are known to induce PPARγ activity.

Peroxisome proliferator-activated receptor gamma
(PPARγ) is a member of the nuclear receptor (NR)
superfamily, which functions as a ligand-dependent
transcription regulator. Due to alternative splicing and
differential promoter utilization, PPARγ exists in two
isoforms, PPARγ1 and PPARγ2. The murine Pparγ2
encodes an additional 30 amino acids (28 amino acids in
human PPARγ) at its N-terminus. PPARγ1 is expressed
www.impactjournals.com/oncotarget
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PPARγ activity is also regulated by posttranslational modifications, including phosphorylation,
sumoylation, ubiquitination and acetylation. Among
these post-translational modifications, phosphorylation
has been extensively studied. The Activation Function 1
(AF1) region of PPARγ is phosphorylated by mitogenactivated protein kinases (MAPKs) (PPARγ1 at Ser82
and PPARγ2 at Ser112), which represses transcriptional
activity by inhibiting ligand binding and altering cofactor
recruitment [7-9]. Phosphorylation of the same residue
by cyclin-dependent kinases, Cdk7 and Cdk9, promotes
PPARγ activity [10, 11]. Recently it was reported
that PPARγ2 is phosphorylated at Ser273 by cyclindependent kinase 5 (CDK5) [12]. Phosphorylation of
PPARγ2 by CDK5 inversely correlates with TZD-induced
insulin sensitivity in human. These studies indicate that
phosphorylation of PPARγ at different sites or even at
the same sites results in different transcriptional and
functional outcomes depending on the physiological
context and the kinases involved. This phenomenon is well
known among other post-translationally modified nuclear
receptors. Several different acetylation sites (K266, 268,
302, and 303) of estrogen receptor alpha (ERα) have
been reported [13, 14]. Acetylation of ERα at lysine 266
and 268 enhances the DNA binding and transactivation
activities of the receptor, however acetylation of lysine
302 and 303 suppresses the transactivation function.
Recent publications showed that PPARγ is acetylated
by p300 or CBP and deacetylated by silent mating type
information regulation 2 homolog 1 (SIRT1). PPARγ
acetylation participated in cellular senescence [15] and
the brown remodeling of white adipose tissue (Lysine
268 and 293) [16]. Even though acetylation has been well
characterized in the androgen receptor (AR) and ERα at
a conserved lysine motif (K(R)xxKK) which is shared
amongst evolutionarily related nuclear receptors [14, 1719], the function of this conserved lysine motif in Pparγ
was not known.
Increased de novo fatty acid synthesis, which
contributes to energy homeostasis and tumor growth,
is a common feature of human tumors. The survival of
breast cancer cells, especially those with ErbB2/Her2
overexpression, is highly dependent upon the lipid
metabolism induced by Pparγ, which protects cells from
palmitate toxicity [20]. Our previously published work
showed that a constitutively active Pparγ1 mutant (PγCA)
collaborated with oncogenic ErbB2 to promote mammary
tumor growth [21].
Herein, we characterized Pparγ1 acetylation at the
conserved lysine motif (RIHKK). Our studies revealed
that Pparγ1 is acetylated at nine distinct lysyl residues.
The acetylation of Pparγ1 lysine 154 was confirmed by a
chemically modified trypsin mapping protocol developed
for histone acetylation mapping. The K155 residue,
which is located in close proximity to the DNA binding
domain, was deacetylated by SIRT1. The Pparγ1 mutant
www.impactjournals.com/oncotarget

K154/155R reduced the acetylation levels assessed
by in vivo labeling. The acetylation-defective mutant
K154/155A or K154/155Q showed reduced interaction
with SIRT1. The Pparγ1 K154/155 determines the
induction of lipogenesis in ErbB2 overexpressing breast
cancer cells. Loss of SIRT1 function and gain of Pparγ1
function converge on common gene signaling pathways. In
summary, these results suggest that the acetylation of the
conserved lysine motif (K154/155) of Pparγ1 determines
lipid synthesis in ErbB2-positive breast cancer cells.

RESULTS
Acetylation of lysyl residues of conserved motif in
Pparγ
Pparγ acetylation has historically been investigated
by using anti-acetyl lysine antibodies [15, 16]. In order
to determine Pparγ acetylation, we firstly performed in
vivo labeling assays. The incorporation of [3H] acetylCoA into Pparγ was only seen in cells transfected with
3xFLAG-tagged Pparγ1, but not control vector (Fig. 1A).
The addition of trichostatin A (TSA), an inhibitor of type I/
II HDACs, or nicotinamide (NA), an inhibitor of Sirtuins,
increased [3H]-labeled Pparγ (Fig. 1A). These results
suggest that the basal acetylation levels of Pparγ are very
low, and endogenous class I/II and III HDACs are both
involved in the deacetylation of Pparγ.
The residues in proximity to Pparγ1 K154/155
resemble the acetylated motif of ERα and AR [14, 17]
and are conserved among different species (Fig. 1B). In
order to determine whether the lysyl residues K154 and
K155 in the conserved motif of Pparγ are acetylated,
we conducted mass spectrometry (MS) of immuneprecipitated 3xFLAG-tagged Pparγ1 from HEK 293 cells.
These lysyl residues contain numerous basic amino acids
which are often resistant to conventional trypsin mapping.
This was confirmed by trypsin and chymotrypsin mapping
(Fig. S1A), which demonstrated that mapping covered
92% of the protein, but omitted the conserved acetylation
motif. Therefore, trypsin mapping was conducted using a
chemical-derivatization protocol [22]. While the sequence
coverage (Fig. S1B) is not as high as conventional trypsin
or chymotrypsin mapping, the spectral counts and Mascot
scores for acetylated peptides were higher, and multiple
peptides with overlapping sequences mapped to the same
site (Fig. S2A, B). A total of nine lysyl residues including
K154 were identified as targets for acetylation in vivo
(Fig. 1C and Fig. S2A). Using 3-dimensional structural
mapping, lysyl residues 156 and 157 of human PPARγ1
(lysyl residues 154 and 155 in mouse Pparγ) are located
in the DNA binding domain in close juxtaposition to the
ligand binding domain (Fig. 1D). The side chain nitrogen
of the K156 (K154 in mouse, bottom yellow residue)
7304
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is approximately 8A˚ from the phosphate backbone of
DNA, too far for a hydrogen bond, and therefore does
not directly contact DNA (orange in image) but rather
appears solvent accessible. This data is consistent with
its observed acetylation by MS. The adjacent K157
(K155 in mouse, top yellow residue) side chain nitrogen
is approximately 13A˚ from the DNA backbone, forms
a hydrogen bond with E378 of human PPARγ but
appears solvent inaccessible. To verify the acetylation of
the conserved lysine motif in Pparγ, an in vivo labeling
assay was performed in HEK 293 cells transfected with
3xFLAG-tagged Pparγ1 wild-type or K154/155R mutant.
Wild-type Pparγ1 was acetylated while the K154/155R
mutation significantly reduced the incorporation of [3H]

acetyl-CoA (Fig. 1E), suggesting that K154/155 are bona
fide acetylation sites.
As NA increased the Pparγ acetylation, we
investigated whether Pparγ1 K154/155 could serve as a
substrate for SIRT1. A synthetic peptide containing the
sites was used as a substrate for an in vitro deacetylation
assay. The kinetic parameters for deacetylation of this
peptide were similar to that of a p53 peptide known to
be deacetylated by SIRT1 (Fig. 1F). Confirmation of the
peptide deacetylation (K155) was obtained by MS (Fig.
1G, H). Thus, consistent with our original findings [13,
17] in which the lysyl residues of a conserved motif (K(R)
xxKK) in ERα and AR are acetylated, and subsequent
studies of other nuclear receptors (NRs) [18, 19, 23-25],

Figure 1: Acetylation of lysyl residues within conserved acetylation motif of Pparγ. (A) The inhibition of either TSA-sensitive

or NAD-dependent deacetylase activity induced Pparγ acetylation assayed by in vivo [3H]-sodium acetate labeling. (B) The conserved
acetylation motif in Pparγ is shown for several species. (C) Tandem MS (MS/MS) spectrum of Pparγ showing the acetylation at K154 (Red
letter), “Ac” indicates lysine (K) residues that is acetylated. (D) A cylinder model for the crystal structure of hPPARγ1 with DNA double
helix (orange color). The lysine 156 and 157 are shown in yellow. (E) Mutant K154/155R significantly reduced Pparγ acetylation. (F) The
deacetylation rate of Pparγ or p53 peptide of different concentrations by SIRT1. The lines are best fits to the Michaelis-Menten equation and
determine the following values for Km and Vmax: PPARγ (•), Km is 60.1 µM, vmax is 0.016s-1; ASp53 (ƀ), Km is 90.5 µM, vmax is 0.013s-1.
(G) HPLC chromatograms of Pparγ peptide deacetylation with SIRT1 enzyme. Untreated diacetylated Pparγ peptide is shown at bottom
chromatogram. (H) MS/MS spectrum of the deacetylated Pparγ. Asterisk indicated deacetylated lysine residue.
www.impactjournals.com/oncotarget
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Mutation of Pparγ1 at K154/155 reduces SIRT1
binding

Pparγ1 is also acetylated at the conserved lysine motif.

The association between Pparγ1 and SIRT1 was
next examined by immune-precipitation and Western

Figure 2: Mutation of Pparγ at K154/155 reduces SIRT1 binding. (A) Schematic diagram of Myc-tagged SIRT1 wild-type.

(B) Schematic diagrams of 3xFLAG-tagged Pparγ1 full length and internal deletion mutants. (C) HEK 293T cells were transfected with
the indicated plasmids. Immuno-precipitations with anti-FLAG antibody were conducted, and Western blot was performed by indicated
antibodies. The abundance of SIRT1, PPARγ internal deletions in input are shown. (D) Schematic diagrams of 3xFLAG-tagged Pparγ1
full length and individual domains. (E) HEK 293T cells were transfected with the indicated plasmids. Immuno-precipitations with antiFLAG antibody were conducted, and Western blot was performed by indicated antibody. The bands for 3x FLAG-tagged Pparγ full
length and individual domains are indicated by an asterisk. (F) Schematic diagrams of 3xFLAG-tagged Pparγ1, Myc-tagged SIRT1 wildtype and catalytic point mutation. (G) HEK 293T cells were transfected with the indicated plasmids. Immuno-precipitations with antiFLAG antibody were conducted, and Western blot was performed by indicated antibody. All experiments were performed at least 3 times,
representative figures are shown.
www.impactjournals.com/oncotarget
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blot analyses. We firstly examined the domains of Pparγ1
required for SIRT1 binding. Expression vectors encoding
Myc-tagged SIRT1 (Fig. 2A) together with FLAGtagged Pparγ1 or internal deletion mutants (Fig. 2B) were
transiently introduced into HEK 293T cells. Immuneprecipitation was performed. Protein expression was
evidenced by Western blot of the input protein using an
anti-FLAG antibody for Pparγ1 and mutants, and an antiMyc antibody for SIRT1 (Fig. 2C). SIRT1 was detected
in immune-precipitated wild-type Pparγ1. Deletion of the
AF-1 domain or ligand binding domain (LBD) of Pparγ1
enhanced relative SIRT1 binding. Deletion of the DNA
binding domain (DBD) and/or hinge region reduced
binding (Fig. 2C). Given that deletion of the DBD and/
or hinge region reduced SIRT1 binding, we determined
whether SIRT1 is associated with the individual DBD or

hinge domains. Expression vectors encoding individual
Pparγ1 domains (Fig. 2D) were co-expressed with SIRT1
expression vector in HEK 293T cells. Western blot with
anti-Myc antibody showed either the DBD or hinge region
of Pparγ1 was sufficient for association with SIRT1. The
relative binding of SIRT1 to the AF1 region and LBD
was reduced compared to wild-type Pparγ1 (Fig. 2E).
We further studied the interaction between the Pparγ1
K154/155 mutation and SIRT1. As shown in Figure 2F
and 2G, both K154/155A and K154/155Q demonstrate
reduced binding to SIRT1. These results suggest that the
DBD and/or hinge regions of Pparγ1 are required for
SIRT1 association and that both the K154/155A and the
K154/155Q mutants have reduced SIRT1 binding ability.

Figure 3: Sirt1 and Pparγ are both required for maintaining essential metabolic pathways in the liver. (A) Schematic

representation of microarray screening of deferentially expressed genes between Sirt1-/- mouse liver and Sirt1+/+ mouse liver. (B) Overlap
of genes regulated by Pparγ overexpression and Sirt1 knockout in mouse liver. (C) KEGG pathways enriched for genes up-regulated
in Pparγ overexpressing and Sirt1 knockout liver. (D). Gene Ontology Biological Processes enriched for genes up regulated in Pparγ
overexpressing and Sirt1 knockout liver. Hypergeometric test used to identify deregulated ontologies associated with Pparγ overexpression
and Sirt1 knockout. Fold induction ≥ 1.5 and P-value ≤ 0.05.
www.impactjournals.com/oncotarget

7307

Oncotarget

SIRT1 deletion and Pparγ gain-of-function govern
common signaling pathways in vivo

and lipid accumulation (Fig. 4A, B). Consistent with the
ability of Pparγ to induce lipid formation, the relative
protein abundance of the adipocyte Protein 2 (aP2) was
induced by Pparγ1 and the Pparγ1 K77R mutant but
not the K154/155A or K154/155Q mutants (Fig. 4C).
Under differentiation conditions, the expression levels
of the cell cycle regulators, cyclin D1 and cyclin E,
were slightly increased or unchanged respectively (Fig.
4C). Next, in order to study the gene expression profile
regulated by Pparγ acetylation, microarray analysis was
performed. Genome-wide expression analysis identified
995 genes differentially expressed in Pparγ1-transduced
MCF10A-NeuT cells (Tables S3). Among these, pathway
analysis identified 127 genes populating the enhanced
lipid metabolism pathway (Fig. 4D and Tables S4). Key
enzymes required for de novo lipogenesis and β-oxidation
are upregulated (highlighted by orange color) by wildtype Pparγ, but not K154/155A or K154/155Q substitution
mutants (Fig. 4E). Comparison of the gene expression
pathways regulated by Pparγ vs. the K154/155Q (Fig. 4F)
showed distinct pathways dependent upon the K154/155
with the loss-of-function (Fig. 4F, I and Tables S5) or
gain-of-function (Fig. 4F, III and Tables S6). Unchanged
pathways are shown in Tables S7. These data suggest that
substitution of lysyl residues with residues that cannot
be acetylated (alanine (K to A) or glutamine (K to Q))
represents PPARγ acetylation-defective mutant in and
that Pparγ acetylation at the conserved lysine motif serves
as a molecular switch of Pparγ-mediated induction of
lipogenesis in breast cancer cells.

Given that Pparγ enhances adipogenesis [26]
and Sirt1 attenuates adipogenesis [27], we investigated
the possibility that SIRT1 deletion and Pparγ gain-offunction may have common gene expression signatures
in vivo. Total RNA from liver samples was isolated from
Sirt1-/- mice and littermate controls [28]. Microarray
analysis identified 262 genes that were significantly
down-regulated and 531 genes that were significantly
increased in Sirt1-/- mouse liver relative to Sirt1+/+ mouse
liver (P < 0.05, Fold > 1.5) (Fig. 3A, B and Table S1).
Gene network analysis populated lipid metabolism as
the major downstream target of Sirt1 (Tables S2). For
the gene expression profile of Ppar gain-of-function, we
took advantage of published data conducted in mouse
liver injected with an adenovirus encoding mPparγ1
[29]. The hepatic genes altered in Sirt1-/- mice were
compared to those regulated by Pparγ1 overexpression. A
significant number of genes (107 genes with 76 expected
giving a fold enrichment of 1.4 and a P-value of 0.0001)
were up-regulated by Pparγ1 overexpression and Sirt1
gene deletion (Fig. 3B). Seven KEGG pathways and 23
Biological Process Gene Ontologies were enriched for
genes up-regulated by Pparγ1 overexpression and Sirt1
gene deletion (Fig. 3C, D). Such pathways were mainly
involved in lipid metabolism, including the biosynthesis
of unsaturated fatty acids, fatty acid metabolism, and fatty
acid oxidation. These data suggested SIRT1 and Pparγ
converge to govern lipid metabolism in vivo.

DISCUSSION

The conserved acetylation sites of Pparγ
determine lipid production

In this report, we have shown that the conserved
acetylation site (K154/155) of Pparγ plays a critical role
in breast cancer cell lipid synthesis. Firstly, we identified
nine distinct acetylation sites in cultured cells by MS, and
further confirmed the acetylation of K154/155 of Pparγ
by in vivo labeling assay. We analyzed the function of
K154/155 acetylation based on the conservation of this
motif across species and evolutionally related nuclear
receptors [14]. Our results showed that acetylationdefective mutants of Pparγ are associated with
decreased lipogenic differentiation in ErbB2-positive
breast cancer cells, as shown by Oil Red O staining,
protein expression of the classic adipocyte marker aP2,
and mRNA expression of multiple lipogenic genes in
microarray analysis. Decreased lipogenic function of
the K154/155A and K154/155Q mutant was not due to
changes of protein structure, cellular localization, and
protein stability (unpublished data). This work provides
a novel mechanism through which Pparγ regulates lipid
metabolism via conserved acetylation sites in breast
cancer cells.
Acetylation is a dynamic post-translational
modification of lysyl residues. Han et al. reported that

Given Sirt1 deacetylates Pparγ and inhibits
adipogenesis, we reasoned that acetylation of Pparγ may
promote lipid synthesis. In order to investigate the role
of the conserved acetylation sites of Pparγ in lipogenesis,
ErbB2 overexpressing breast cancer cells were used
and lysyl residues were substituted with alanine (K to
A) or glutamine (K to Q) to generate residues that were
incapable of being acetylated. Substitution mutations
(K154/155A, K154/155Q and K154/155R) of Pparγ1
K154/155 were generated, and transduced into MCF10ANeuT cells. K77R of Pparγ1, a Pparγ mutant that is
defective in SUMOylation [30, 31], was used as a
positive control since this mutant induces adipogenesis
in NIH3T3 cells. Following a differentiation protocol,
Oil Red O staining followed by subsequent quantitative
measurement was used to examine the lipid accumulation.
Pparγ induced lipid accumulation which was further
enhanced by Pparγ1 K77R (Fig. 4A). In contrast, the
Pparγ1 K154/155A and the K154/155Q mutants were
defective in the induction of adipogenic differentiation
www.impactjournals.com/oncotarget
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Figure 4: Acetylation-defective mutant of Pparγ is associated with decreased lipogenesis. (A) MCF10A-NeuT cells expressing

various mutants of Pparγ were cultured until they were confluent, after 2 days, cells were stained with Oil Red O, and photographed. (B)
Quantitative analysis of lipids in cells shown in (A) was performed by measuring the OD 520 nm of the Oil Red O stained cells eluted
with 4% Igepal CA-40 in isopropanol (v/v). The results are shown as the average of three experiments; the bars indicate mean ± SEM. (C)
Total cellular proteins from cells subjected to the same experimental protocol as in (A) were collected, and analyzed by Western blot as
indicated. (D) Heat map of genes of lipid metabolism differentially regulated by Pparγ and vector control. (E) Schematic representation of
the key enzymes of lipogenic signaling pathway. Genes upregulated by Pparγ are highlighted (orange color). (F) The genes differentially
regulated in MCF10A-NeuT cells expressing wild-type Pparγ or Pparγ acetylation mutant were analyzed by the Ingenuity Pathway. The
top five Canonical Pathways were listed corresponding to the loss of function with Pparγ acetylation mutant (I), the gain of function (III)
and those unchanged by acetylation (II).
www.impactjournals.com/oncotarget
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association with SIRT1. These data are consistent with
our MS data, where all nine acetylation lysyl residues
identified by MS are located in the DNA binding domain
and hinge domain of Pparγ. Our results indicate that
SIRT1 binds and deacetylates Pparγ. This led us to
investigate the pathways regulated by SIRT1 and Pparγ
in vivo. As expected, a significant number of genes (107
genes) were up-regulated by Pparγ overexpression and
Sirt1 gene deletion. KEGG pathways and Biological
Process Gene Ontologies populated lipid metabolism as
the major term, including the biosynthesis of unsaturated
fatty acids, fatty acid metabolism, and fatty acid oxidation.
Recent studies have shown that the function of SIRT1
in metabolic homeostasis requires NAD+-dependent
deacetylase activity. Sterol regulatory element binding
protein (SREBP) family proteins are critical regulators
of lipogenesis and cholesterologenesis. Walker, et al.
and Ponugoti, et al. showed that SIRT1 can directly
deacetylate SREBPs, and that SIRT1 activity is important
in the fasting-dependent attenuation of SREBP function
[32, 33]. Several other nuclear receptors regulated by
acetylation and deacetylation are also involved in lipid
metabolism [34, 35]. Li, et al. reported that SIRT1 directly
deacetylates LXRs, resulting in increased LXRs turnover
and enhanced target gene expression [34]. LXRs are
nuclear receptors that function as cholesterol sensors and
regulate whole body cholesterol and lipid homeostasis.
SIRT1 also regulates bile acid homeostasis through direct
deacetylation of FXR. Down-regulation of hepatic SIRT1
increases FXR acetylation with deleterious metabolic
outcomes [35]. More recently, Li et al. showed that a
gain-of-function SIRT1 promotes “browning” of WAT by
deacetylating Pparγ at Lys268 and Lys293 [16]. Herein,
we showed that loss-of-function of SIRT1 and gain-offunction of Pparγ converge on liver lipid metabolism. The
interaction between Pparγ and SIRT1 potentially controls
the acetylation and deacetylation status of Pparγ protein.
Therefore, deacetylation of Pparγ by SIRT1 could serve
as a molecular switch that acts as key metabolic sensor.
Enhanced lipogenesis is a hallmark of cancer
cells [36]. This especially holds true in ErbB2-positive
human breast cancer cells, which have a high degree of
fat storage [37]. We have previously shown that active
Pparγ promotes ErbB2-positive breast cancer growth
through enhanced angiogenesis [21]. In the current study,
we investigated the role of Pparγ K154/155 acetylation
on lipid production in ErbB2-positive breast cancer
cells. Adipogenic differentiation assays were performed
to evaluate the function of these mutants in MCF10A
cells transformed with oncogene NeuT. Consistent with
data from Yamashita et al., Pparγ2 induced adipogenesis
in NIH3T3 cells and a sumoylation-defective K107R
mutant of Pparγ2 stimulates adipogenesis more robustly
than the wild-type [31]. We showed that Pparγ induced
lipid accumulation in MCF10A-NeuT cells, and the
K77R mutant of Pparγ1 increased lipogenesis. Oil Red

acetylation and deacetylation of Pparγ is regulated by
p300 and SIRT1 in the process of cell senescence [15],
however no acetylated residues were identified. Recent
publication by Li et al. mapped 5 acetylated lysyl residues
(98, 107, 218, 268, and 293) in mouse Pparγ2 (68, 77,
188, 238 and 263 in mPparγ1) by MS [16]. Among them,
two evolutionally conserved residues in the helix 2-helix
region, Lys268 and Lys293 were further investigated.
These studies indicated that deacetylation of Pparγ at
Lys268 and Lys293 by SIRT1 is required for maintaining
the brown remodeling of white adipose tissue [16].
However, these prior studies did not analyze acetylation
of the conserved lysine motif (K(R)xxKK) in Pparγ due to
the limited coverage of the MS protocol used. Similar to
the N-terminus of histone, the region “RIHKKSRNKC”
is enriched with an overwhelming number of arginine and
lysyl residues. Small fragments obtained by conventional
trypsin digestion cannot be detected by conventional
MALDI-TOF. Therefore, in our studies, trypsin mapping
after a chemical-derivatization protocol was used to
render lysine positions resistant to trypsin cleavage. This
method increased the spectral counts and Mascot scores
of acetylated peptides. A total of nine lysyl residues
including K154 were identified. Among them, K188 and
K238 in Pparγ1 correspond to K218 and K268 in Pparγ2,
which were reported by Li et al [16]. Discrepancies in
the identified Pparγ acetylation sites may be the results of
two different experimental approaches and/or the choice
of Pparγ isoform choose in these two studies. In our
approach, we transfected HEK 293 cells with mPparγ1,
and treated with TSA and NA, while in their report, HEK
293 cells were co-transfected with expression vectors
encoding mPparγ2 and acetyltransferase Cbp, followed
by treatment with Rosiglitazone (a PPARγ agonist).
Quantification of K154/155 acetylation was performed.
The results suggest that the native acetylation levels of
Pparγ are very low (1%), consistent with Li et al [16] in
which the acetylation of mPparγ2 K268 and K293 was
detected by MS only in the presence of Cbp. Acetylation
of K155 was not detected by MS, most likely due to its
inaccessibility by solvent as shown by a 3-dimensional
structure analysis. Using an in vitro deacetylation assay,
we demonstrated that a Pparγ peptide harboring acetylated
K154 and K155 residues is a substrate for SIRT1
deacetylation. Finally, in our in vivo labeling studies, the
Pparγ mutant K154/155R conveyed significantly reduced
incorporation of [3H] acetyl-CoA. Together, these results
demonstrate that K154 and 155 are bona fide acetylation
sites in vivo and are substrates for SIRT1 deacetylation.
Han et al. reported the catalytic domain of SIRT1
is necessary and sufficient for the interaction between
Pparγ and SIRT1 and that the catalytically inactive
SIRT1 mutant H363Y conveyed reduced association
with Pparγ [15]. In our studies, the DBD and/or hinge
regions of Pparγ were required for SIRT1 association.
The K154/155A or K154/155Q mutants showed reduced
www.impactjournals.com/oncotarget
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O staining, lipogenic protein expression and genomewide expression analysis indicated that both K154/155A
and K154/155Q mutants were defective in the induction
of lipid accumulation and adipogenic differentiation. As
shown in Figure 4, key enzymes and transcription factors
required for de novo lipogenesis (SREBP, Insig and SCD)
and β-oxidation (ACAA and MCD) are up-regulated
by Pparγ wild-type, but not K154/155A or K154/155Q
mutants. K154/155R mutant exhibited similar effect to
Pparγ wild type (data not shown). In our prior publication,
we showed that ERα acetylation governs ligand sensitivity,
as all substitution mutants (K to A, Q and R) induced ERα
hormone sensitivity [14]. Recently, Daniel et al. identified
the progesterone receptor (PR) acetylation site within the
conserved lysine motif KxKK (amino acids 638–641)
[18]. Mutation of these three lysyl residues to alanine (A)
or glutamine (Q) resulted in delayed phosphorylation,
nuclear entry and transactivation of c-Myc, a known rapid
response gene. In summary, SIRT1 deacetylates Pparγ at
a conserved lysine motif. SIRT1 deletion and Pparγ gainof-function converge to govern lipid metabolism in vivo.
We conclude that acetylation of Pparγ increases lipid
synthesis. These data suggest that the Pparγ acetylation
of the lysine motif serves as a molecular switch governing
Pparγ-mediated induction of lipogenesis in ErbB2/
Her2 overexpressing breast cancer cells. It is of great
importance to further investigate if lipogenesis regulated
by acetylation of the Pparγ lysine motif (K154/155)
contributes to the progression of ErbB2-positive breast
cancer.

primers. The individual domain of Pparγ1 was digested by
XbaI/BamHI from GAL4-DBD-HA-Pparγ1-AF1, DBD,
Hinge and LBD (Gifts from Dr. Z. [40]), and then was
subcloned into p3xFLAG-CMV 10 vector. The integrity
of all constructs was confirmed by sequence analysis.
The Myc-tagged wild-type and mutant (H363Y) SIRT1
expression constructs in pcDNA3.1 were previously
described [41].
Cell transfection and infection were performed
as previously described [42, 43]. Retroviruses were
prepared by transient cotransfection of vector expressing
Pparγ1, mutants or empty vector together with the helper
viral vector into 293T cells using calcium phosphate
precipitation. The retroviral supernatants were harvested
48 h after transfection and filtered through a 0.45 µm
filter. Mammary epithelial cells MCF10A-NeuT cells
were incubated with fresh retroviral supernatants in the
presence of 8 µg/ml polybrene for 24 hrs, cultured for a
further 48 hrs, and subjected to different assays.

In vivo [3H]-acetyl-CoA labeling.
Labeling of Pparγ was conducted using the
previously described protocol with some modifications
[44]. Briefly, one 10-cm plate of 293 cells was used for in
vivo acetyl group labeling. The cells transfected either with
expression vector or control were maintained in DMEM
w/ 10% FBS at over 80% confluence. The cells were first
were treated with 1µM TSA and 10 mM NA for 4 hours,
and then transferred to DMEM medium containing 1µM
TSA, 10 µM NA and 1 mCi/ml [3H]-sodium acetate (75–
150 mCi/mmol) (Perkin Elmer) for 1hr. Cells were washed
twice with ice-cold PBS and lysed in RIPA buffer with
freshly added protease inhibitor cocktail supplemented
with fresh DTT (1 mM) and PMSF (1 mM). The lysates
were centrifuged at 14,000 rpm for 15 min at 4°C.
Supernatants were incubated with antibody conjugated
to agarose beads, for 6 to 12 hrs at 4°C. Immunopurified
proteins were resolved on SDS–PAGE gels. Gels were
either staining with Coomassie blue and then dried, or
directly dried and subjected to autoradiography at -70°C
for 2-4 weeks.

MATERIALS AND METHODS
Cell culture, plasmid DNA, and transfection
The HEK293, HEK293T cells were maintained in
Dulbecco’s Modification of Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum, 1% penicillin,
and 1% streptomycin. MCF10A-NeuT cells were cultured
as previously described [38]. MCF10A-NeuT cells
transduced with Pparγ1 or mutants were maintained in
Dulbecco’s Modification of Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum, 1% penicillin,
and 1% streptomycin. All cells were cultured in humidified
atmosphere with 5% CO2 at 37°C. Rosiglitazone and
15d-PGJ2 are from Cayman Chemical.
The expression vectors encoding mouse Pparγ1
are previously described [39]. The Pparγ1 point mutants
were derived by site-directed mutagenesis using sequencespecific primers. The wild-type and point mutants of
Pparγ1 were individually cloned into p3xFLAG-CMV
10 vector (Sigma) and MSCV-IRES-GFP vector. The
internal deletion mutants of Pparγ1 were subcloned
into p3xFLAG-CMV 10 vector using sequence-specific
www.impactjournals.com/oncotarget

Identification of Pparγ acetylated lysine residue
using MS
Preparation and proteolytic digestion of
Pparγ: 3xFLAG-tagged Pparγ1 was purified by
immunoprecipitation, using anti-FLAG M2 affinity gel,
and the bound material was eluted using a soft SDSelution protocol in order to selectively elute the bound
recombinant protein and not the anti-FLAG antibody.
This eluent was concentrated on a speedvac and further
separated on SDS-PAGE and stained with Coomassie
blue. The major band at 55 kDa was cut. The gel pieces
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were completely dehydrated and subsequently reduced
and alkylated. To improve coverage of the basic regions
of Pparγ1 sequences, the gel isolated protein was mapped
using a modified trypsin mapping protocol as below.
Chemical modification of lysine and tryptic mapping
of acetylation site: Chemical modification was achieved
after the reduction/alkylation steps. In detail, the gel was
hydrated with 10 µl of deuterated acetic anhydride, 20
µl of 100 mM ABC (pH 8), and mixing. The acetylation
reaction is fast and results in acidification of the solution,
so 70 µl of 100 mM ABC is immediately added and the
solution is incubated at 37°C for 5 minutes. The pH is
measured within the first 5 minutes and adjusted to 7-8.
After an additional 30 minute incubation at 37°C, the
supernatant is removed and the gel pieces are washed
twice with water, and then dehydrated by successive
washes (with vortexing, as above) in 100 µl of 50 mM
ABC, then 100 µl 50 mM ABC with 50% acetonitrile (50ACN), and finally 100% ACN. This chemical treatment
derivatized lysyl residues with a deuterated acetyl group
(a 45Dalton mass increase) and rendered lysine positions
resistant to trypsin cleavage. Deuterated acetic anhydride
was used to allow differentiation from the native acetyl
group (a 42 Dalton modification group).
Trypsin (200 ng in 50 µl of 50 mM ABC) is then
added to hydrate the gel slices. After an hour at room
temperature, additional 50 mM ABC and 10% ACN was
added to ensure that the gel pieces were always covered
with solvent. The digest was transferred to 37°C and
digested overnight. Next, the supernatant was transferred
to LoBind tubes (Eppendorf) and the remaining peptides
were extracted by adding sufficient 50% ACN, 5%
Trifluoroacetic acid to cover the gels and by vortexing
for 25 minutes. This step was repeated and each of the
three supernatants were combined and lyophilized in a
Speedvac.
Mass spectrometry analysis: Dehydrated peptides
were resuspended in 5% acetonitrile, 0.05% formic acid
and immediately loaded on a nano-spray tip for LC-MS/
MS analysis. 10 - 15% of the peptide digest is loaded on
a Magic C18 AQ (Michrom) nanospray tip, packed to
5 cm. This tip was loaded, using a pressure bomb, and
washed, after installation on the HPLC of a Thermo
LTQ mass spectrometer, with 5% methanol, 0.1% formic
acid, for 10 min with a flow rate of 600 nl/minute (about
10 column volumes = 6.6 µl) The peptide digests were
analyzed in an LC-MS/MS run, using a 5-15 % methanol
gradient over 2.5 minutes, followed by a 15-60% methanol
gradient for 67 minutes, a 60% methanol isocratic step of
4 minutes, ending with a 3-minute 95% methanol step,
with all solvents containing 0.1% formic acid. A full MS
survey scan is performed every 3 seconds and the top 7
peaks are selected to produce MS/MS fragmentation
spectrum. In order to confirm if K154/155 is acetylated,
the same peptide digest was run a second time, under
identical HPLC conditions. With the mass spectrometer
www.impactjournals.com/oncotarget

programmed with an inclusion filter of 383-431 m/z to
select for doubly charged peptides in the size range of
the IHKKSR hexa-peptide in its unmodified and fully
derivatized states. This selective method allows for the
determination of the relative frequency of the modified
and unmodified IHKKSR peptides, by evaluating the
spectral count ratios.
Mapping of proteolytic peptide fragments and
acetylation sites: The MS and MS/MS fragmentation
spectrum data were used in a Mascot search of the whole
mouse proteome. To identify peptide sequences modified
with acetyl groups, a custom database, containing
the recombinant Pparγ sequence, was also searched.
The following search criteria were used for selecting
fragmentation spectra that map to proteolytic peptides:
peptide tolerance = -0.8 to +0.5, a minimum ion score of
15, and a fragmentation spectrum, containing fragment
ions that either include or flank the acetylated amino
acid position. Mascot searches were conducted, allowing
for multiple positive charge-states, 2, 3, or 4 missed
cleavage sites, fixed S-carboxyamidomethyl modification
of cysteine and variable methionine oxidation and lysine
acetylation. Mascot searches use trypsin digestion, but
allow for 4 or 5 missed trypsin cleavages, and variable
deuterated acetyl (45 Da) and native acetyl (42 Da)
modification.

Determination of the deacetylation site in Pparγ
peptide in vitro
To determine the Michaelis-Menten curves of
SIRT1-catalyzed deacetylation of Pparγ and p53, the Pparγ
peptide CDLNCRIHXXSRNKCQY and the p53 peptide
GSRAHSSHLXSXXGQSTSRHRXLMFXTEGPDSD
where “X” is AcK (Rockefeller Proteomics Resource) .
The enzymatic reaction was initiated by adding SIRT1
into the solution containing the peptide. For the Pparγ
peptide, the Pparγ peptide of different concentrations was
incubated with 4 μM SIRT1, 500 μM NAD, and 500 μM
DTT in the 100 mM KH2PO4 buffer of pH 8. The reaction
was quenched with 10% TFA after 10 minutes incubation
at 37oC. The Pparγ peptide and the deacetylated peptide
were separated by HPLC (Hitachi LaChrom Elite HPLC
system) using a C18 5 µm column (Waters) with gradient
acetonitrile and 0.1%TFA as eluent. The areas of peaks
for peptides were used for quantification. For the p53
peptide, the p53 peptide of different concentrations was
incubated with 4 μM SIRT1, 500 μM NAD in 100 mM
KH2PO4 buffer of pH 8 at 37oC. The enzymatic product
acetyl adenosine diphosphate ribose (AADPR) was
monitored by HPLC using C18 column (Waters) with 20
mM NH4OAc as eluent. The area of AADPR peak was
used for quantification. The turnover rate versus the Pparγ
peptide and p53 peptide concentration was fitted with
Kaleida Graph software, and Km and kcat were determined.
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In order to determine the deacetylation site in the
Pparγ peptide, 200 μM Pparγ was incubated with 4 μM
SirT1 for 20 minutes in the reaction of 1.25 mL. The
deacetylated peptide was separated from the Pparγ peptide
by HPLC as previously described and collected. The
lyophilized product was analyzed for mass spectrometry
at the Proteomics Resource Center in the Rockefeller
University. In the analysis, the samples of Pparγ and
the deacetylated Pparγ were separately mixed with 50%
aqueous methanol solution (vol:vol=1:1) and loaded
into a glass nanospray PicoTip (New Objectives). The
samples were analyzed by nano-electrospray tandem mass
spectrometry with an ABI QSTAR mass spectrometer.

correction and normalization were done using Iterative
plier 16 with GeneSpring V12.0 software (Agilent, Palo
Alto, CA, USA). 1.5-fold (p value <0.05) differentially
expressed gene list was generated. The differentially
expressed gene list was loaded into Ingenuity Pathway
Analyses (IPA) 8.0 software (http://www.ingenuity.com)
to perform biological network and functional analysis.
Expression profiles are displayed using Treeview.
Microarray analysis was also performed with total RNA
samples from Sirt1+/+ and Sirt1-/- mice liver [28]. Pathway
analysis was performed using and Kyoto Encyclopedia
of Genes and Genomes (KEGG). Gene Ontology (GO)
analysis was performed for gene functions.

Immunoprecipitation and Western blot
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